Your browser doesn't support javascript.
loading
Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction.
Wiehe, Kevin; Saunders, Kevin O; Stalls, Victoria; Cain, Derek W; Venkatayogi, Sravani; Martin Beem, Joshua S; Berry, Madison; Evangelous, Tyler; Henderson, Rory; Hora, Bhavna; Xia, Shi-Mao; Jiang, Chuancang; Newman, Amanda; Bowman, Cindy; Lu, Xiaozhi; Bryan, Mary E; Bal, Joena; Sanzone, Aja; Chen, Haiyan; Eaton, Amanda; Tomai, Mark A; Fox, Christopher B; Tam, Ying K; Barbosa, Christopher; Bonsignori, Mattia; Muramatsu, Hiromi; Alam, S Munir; Montefiori, David C; Williams, Wilton B; Pardi, Norbert; Tian, Ming; Weissman, Drew; Alt, Frederick W; Acharya, Priyamvada; Haynes, Barton F.
Afiliação
  • Wiehe K; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA. Electronic address: kevin.wiehe@duke.edu.
  • Saunders KO; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA; Department of Microbiology and Molecular Genetics, Duke University School of Medicine, Durham, NC 27710, USA; Department of Integ
  • Stalls V; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Cain DW; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Venkatayogi S; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Martin Beem JS; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Berry M; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Evangelous T; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Henderson R; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Hora B; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Xia SM; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Jiang C; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Newman A; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Bowman C; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Lu X; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Bryan ME; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Bal J; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Sanzone A; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Chen H; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Eaton A; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
  • Tomai MA; Corporate Research Materials Lab, 3M Company, St. Paul, MN 55144, USA.
  • Fox CB; Access to Advanced Health Institute, Seattle, WA 98102, USA.
  • Tam YK; Acuitas, Inc, Vancouver, BC, Canada.
  • Barbosa C; Acuitas, Inc, Vancouver, BC, Canada.
  • Bonsignori M; Translational Immunobiology Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Muramatsu H; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Alam SM; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Montefiori DC; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
  • Williams WB; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA; Department of Integrative Immunology, Duke Uni
  • Pardi N; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Tian M; Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.
  • Weissman D; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Alt FW; Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.
  • Acharya P; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
  • Haynes BF; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA; Department of Integrative Immunology, Duke University School of Medicine, Durham, NC 27710, USA. Electronic address: barton.hayn
Cell Host Microbe ; 32(5): 693-709.e7, 2024 May 08.
Article em En | MEDLINE | ID: mdl-38670093
ABSTRACT
A major goal of HIV-1 vaccine development is the induction of broadly neutralizing antibodies (bnAbs). Although success has been achieved in initiating bnAb B cell lineages, design of boosting immunogens that select for bnAb B cell receptors with improbable mutations required for bnAb affinity maturation remains difficult. Here, we demonstrate a process for designing boosting immunogens for a V3-glycan bnAb B cell lineage. The immunogens induced affinity-matured antibodies by selecting for functional improbable mutations in bnAb precursor knockin mice. Moreover, we show similar success in prime and boosting with nucleoside-modified mRNA-encoded HIV-1 envelope trimer immunogens, with improved selection by mRNA immunogens of improbable mutations required for bnAb binding to key envelope glycans. These results demonstrate the ability of both protein and mRNA prime-boost immunogens for selection of rare B cell lineage intermediates with neutralizing breadth after bnAb precursor expansion, a key proof of concept and milestone toward development of an HIV-1 vaccine.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos B / Anticorpos Anti-HIV / HIV-1 / Vacinas contra a AIDS / Anticorpos Neutralizantes Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos B / Anticorpos Anti-HIV / HIV-1 / Vacinas contra a AIDS / Anticorpos Neutralizantes Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article